Cancer Policy HHS issues direct final rule to reduce reliance on animal testing September 25, 2026Vol.52 No.35By Claire Marie Porter
Drugs & Targets FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma September 25, 2026Vol.52 No.35
Drugs & Targets FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component September 25, 2026Vol.52 No.35
Drugs & Targets FDA grants Priority Review to perioperative IMFINZI + enfortumab vedotin for muscle-invasive bladder cancer September 25, 2026Vol.52 No.35
Cancer Policy FDA’s expedited IND pilot aims to shorten the timeline between drug development and first-in-human clinical trials September 18, 2026Vol.52 No.34
Drugs & Targets FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 18, 2026Vol.52 No.34
Drugs & Targets FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC September 18, 2026Vol.52 No.34
Cancer Policy Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI September 11, 2026Vol.52 No.33By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to iberdomide combination for MM September 11, 2026Vol.52 No.33
Drugs & Targets FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer September 11, 2026Vol.52 No.33
